Orally active antioxidant; vascular protectant; antiatherosclerotic;
Succinobucol is a metabolically stable derivative of the antioxidant drug probucol that poses a distinct pharmacological from. Succinobucol is an orally active vascular protectant that exhibits antiatherosclerotic properties in multiple animal models and in humans. It inhibits the release of proinflammatory cytokines, TNF-a, IL-1b, and IL-6 in hPBMC activated by LPS.
Succinobucol (succinyl ester of probucol) is a lipid-lowering compound with anti-inflammatory and antioxidant properties. Recent experimental evidence has highlighted the potential neuroprotective effects of succinobucol. In the present study, cultured neuroblastoma (SH-SY5Y) cells were used to investigate mechanisms mediating the
The Journal of pharmacology and experimental therapeutics, 308(3), 820-829 (2003-11-18)
Atherosclerosis is a disease of oxidative stress and inflammation. AGI-1067 [butanedioic acid, mono[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-,hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis (1,1-dimethylethyl)phenyl] ester] is a metabolically stable derivative of, yet pharmacologically distinct from, the antioxidant drug probucol. It is a member of a novel class of orally active
Succinobucol is a phenolic antioxidant with anti-inflammatory and antiplatelet effects. Given the importance of oxidant stress in modulating platelet-platelet and platelet-vessel wall interactions, the aim of this study was to establish if antioxidant activity was responsible for the antiplatelet activity
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.